Emergent Biosolutions Company Profile (NYSE:EBS)

About Emergent Biosolutions

Emergent Biosolutions logoEmergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID). It also develops and commercializes therapeutics in areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Its two operating divisions include Biodefense and Biosciences. The Biodefense division is a pharmaceutical business focused on countermeasures that address public health threats, including chemical, biological, radiological, nuclear and explosives (CBRNE) threats, as well as EID. The Biosciences division is a pharmaceutical business focused on therapeutics in hematology/oncology with secondary on transplantation, infectious disease and autoimmunity.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NYSE
  • Symbol: EBS
  • CUSIP: 29089Q10
Key Metrics:
  • Previous Close: $29.95
  • 50 Day Moving Average: $30.41
  • 200 Day Moving Average: $29.50
  • 52-Week Range: $24.47 - $44.38
  • Trailing P/E Ratio: 28.36
  • Foreward P/E Ratio: 12.58
  • P/E Growth: 0.65
  • Market Cap: $1.21B
  • Outstanding Shares: 40,498,000
  • Beta: 1.02
Profitability:
  • Net Margins: 9.12%
  • Return on Equity: 10.42%
  • Return on Assets: 6.52%
Debt:
  • Debt-to-Equity Ratio: 0.45%
  • Current Ratio: 4.35%
  • Quick Ratio: 3.62%
Additional Links:
Companies Related to Emergent Biosolutions:

Analyst Ratings

Consensus Ratings for Emergent Biosolutions (NYSE:EBS) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $39.40 (31.55% upside)

Analysts' Ratings History for Emergent Biosolutions (NYSE:EBS)
Show:
DateFirmActionRatingPrice TargetDetails
1/30/2017Chardan CapitalReiterated RatingBuy$47.00View Rating Details
1/9/2017Cowen and CompanyReiterated RatingHoldView Rating Details
10/1/2016Wells Fargo & CompanySet Price TargetBuy$41.00View Rating Details
8/5/2016J P Morgan Chase & CoLower Price TargetOverweight$45.00 -> $36.00View Rating Details
6/28/2016Singular ResearchLower Price TargetBuy$44.00 -> $40.00View Rating Details
3/6/2015Summer StreetReiterated RatingBuy$35.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Emergent Biosolutions (NYSE:EBS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017        
2/23/2017Q4 2016$0.48$0.74$120.45 million$151.66 millionViewListenView Earnings Details
11/7/2016Q3$0.26$0.58$112.30 million$142.91 millionViewListenView Earnings Details
8/4/2016Q2($0.17)($0.18)$111.20 million$101.49 millionViewListenView Earnings Details
5/5/2016Q1($0.07)$0.16$101.83 million$111.00 millionViewListenView Earnings Details
2/25/2016Q4$0.70$0.78$168.07 million$168.10 millionViewListenView Earnings Details
11/5/2015Q315$0.55$0.83$151.42 million$164.90 millionViewListenView Earnings Details
8/6/2015Q215$0.18$0.36$114.25 million$126.10 millionViewListenView Earnings Details
5/7/2015Q1($0.45)($0.50)$62.70 million$63.60 millionViewListenView Earnings Details
3/5/2015Q115$0.69$0.75$147.00 million$148.00 millionViewListenView Earnings Details
11/6/2014Q414$0.52$0.49$126.90 million$138.00 millionViewListenView Earnings Details
8/7/2014Q214$0.32$0.25$109.25 million$110.30 millionViewListenView Earnings Details
5/8/2014Q114($0.14)($0.55)$57.30 million$53.90 millionViewListenView Earnings Details
3/6/2014Q413$0.36$0.42$93.83 million$94.10 millionViewListenView Earnings Details
11/7/2013Q313$0.21$0.37$79.13 million$89.10 millionViewListenView Earnings Details
8/5/2013Q2 2013$0.21$0.29$75.73 million$82.40 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.14)($0.22)$46.17 million$43.10 millionViewListenView Earnings Details
3/7/2013Q4 2012$0.44$0.44$95.09 million$94.61 millionViewListenView Earnings Details
11/1/2012Q312$0.22$0.18$73.53 million$66.60 millionViewN/AView Earnings Details
8/2/2012$0.21$0.21ViewN/AView Earnings Details
5/3/2012($0.18)($0.19)ViewN/AView Earnings Details
3/8/2012$0.72$0.78ViewN/AView Earnings Details
11/3/2011($0.04)$0.04ViewN/AView Earnings Details
8/4/2011$0.33$0.40ViewN/AView Earnings Details
5/5/2011($0.52)($0.64)ViewN/AView Earnings Details
3/10/2011$0.67$0.76ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Emergent Biosolutions (NYSE:EBS)
Current Year EPS Consensus Estimate: $2.08 EPS
Next Year EPS Consensus Estimate: $2.38 EPS

Dividends

Dividend History for Emergent Biosolutions (NYSE:EBS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Emergent Biosolutions (NYSE:EBS)
Insider Ownership Percentage: 17.20%
Institutional Ownership Percentage: 89.61%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/17/2017Adam HaveyEVPSell8,438$29.75$251,030.50View SEC Filing  
1/17/2017Sue BaileyDirectorSell19,424$29.78$578,446.72View SEC Filing  
1/10/2017Daniel Abdun-NabiInsiderSell28,240$31.28$883,347.20View SEC Filing  
12/13/2016Ronald RichardDirectorSell5,900$34.09$201,131.00View SEC Filing  
6/6/2016George A JoulwanDirectorSell4,700$44.12$207,364.00View SEC Filing  
6/1/2016Daniel Abdun-NabiCEOSell8,699$43.74$380,494.26View SEC Filing  
5/27/2016Fuad El-HibriMajor ShareholderSell9,835$43.50$427,822.50View SEC Filing  
5/26/2016Fuad El-HibriMajor ShareholderSell39,759$43.13$1,714,805.67View SEC Filing  
5/25/2016Fuad El-HibriMajor ShareholderSell85,000$42.52$3,614,200.00View SEC Filing  
5/25/2016Zsolt HarsanyiDirectorSell27,867$42.33$1,179,610.11View SEC Filing  
5/24/2016Fuad El-HibriChairmanSell20,000$42.26$845,200.00View SEC Filing  
5/23/2016Fuad El-HibriChairmanSell45,000$42.62$1,917,900.00View SEC Filing  
5/20/2016Daniel Abdun-NabiCEOSell8,701$42.00$365,442.00View SEC Filing  
5/19/2016Jerome M HauerDirectorSell3,134$41.22$129,183.48View SEC Filing  
5/13/2016Louis W SullivanDirectorSell47,631$39.21$1,867,611.51View SEC Filing  
5/12/2016Fuad El-HibriMajor ShareholderSell25,000$38.71$967,750.00View SEC Filing  
5/12/2016Jerome M HauerDirectorSell4,700$38.50$180,950.00View SEC Filing  
5/11/2016Louis W SullivanDirectorSell9,969$39.25$391,283.25View SEC Filing  
4/22/2016Fuad El-HibriMajor ShareholderSell4,209$40.50$170,464.50View SEC Filing  
4/18/2016Daniel Abdun-NabiCEOSell8,702$40.17$349,559.34View SEC Filing  
4/18/2016Fuad El-HibriMajor ShareholderSell20,791$40.50$842,035.50View SEC Filing  
4/6/2016Fuad El-HibriMajor ShareholderSell50,000$39.00$1,950,000.00View SEC Filing  
4/6/2016Robert KramerEVPSell21,786$38.90$847,475.40View SEC Filing  
4/4/2016Robert KramerEVPSell21,788$36.90$803,977.20View SEC Filing  
4/1/2016Robert KramerEVPSell43,572$35.56$1,549,420.32View SEC Filing  
3/14/2016Adam HaveyEVPSell4,359$33.96$148,031.64View SEC Filing  
3/14/2016Jerome M HauerDirectorSell2,350$33.88$79,618.00View SEC Filing  
3/11/2016Adam HaveyEVPSell11,112$33.84$376,030.08View SEC Filing  
3/11/2016Louis W SullivanDirectorSell14,879$34.03$506,332.37View SEC Filing  
3/7/2016Marvin L WhiteDirectorSell33,134$35.42$1,173,606.28View SEC Filing  
1/4/2016Sue BaileyDirectorSell11,520$38.79$446,860.80View SEC Filing  
12/30/2015Ronald RichardDirectorSell21,600$40.00$864,000.00View SEC Filing  
12/24/2015Daniel Abdun-NabiCEOSell63,209$39.06$2,468,943.54View SEC Filing  
11/19/2015Fuad El-Hibrimajor shareholderSell17,871$37.50$670,162.50View SEC Filing  
11/13/2015Fuad El-Hibrimajor shareholderSell13,013$36.50$474,974.50View SEC Filing  
11/12/2015Barry LabingerEVPSell36,126$35.64$1,287,530.64View SEC Filing  
11/9/2015Fuad El-Hibrimajor shareholderSell13,225$35.50$469,487.50View SEC Filing  
11/6/2015Fuad El-Hibrimajor shareholderSell13,450$34.50$464,025.00View SEC Filing  
11/3/2015Fuad El-Hibrimajor shareholderSell13,689$33.50$458,581.50View SEC Filing  
9/11/2015Sue BaileyDirectorSell6,080$32.37$196,809.60View SEC Filing  
8/13/2015George A JoulwanDirectorSell7,200$34.72$249,984.00View SEC Filing  
7/20/2015Fuad El-HibriChairmanSell234$34.50$8,073.00View SEC Filing  
7/13/2015Ronald RichardDirectorSell4,922$34.00$167,348.00View SEC Filing  
6/29/2015Ronald RichardDirectorSell4,923$32.76$161,277.48View SEC Filing  
6/22/2015Fuad El-HibriMajor ShareholderSell74,564$32.60$2,430,786.40View SEC Filing  
6/16/2015Louis W SullivanDirectorSell13,457$31.33$421,607.81View SEC Filing  
6/15/2015Adam HaveyEVPSell36,298$31.55$1,145,201.90View SEC Filing  
6/15/2015Fuad El-HibriMajor ShareholderSell45,436$32.18$1,462,130.48View SEC Filing  
1/20/2015Fuad El-HibriMajor ShareholderSell15,325$27.67$424,042.75View SEC Filing  
12/26/2014Ronald RichardDirectorSell5,000$28.00$140,000.00View SEC Filing  
12/17/2014Ronald RichardDirectorSell5,000$27.00$135,000.00View SEC Filing  
12/11/2014Fuad El-HibriMajor ShareholderSell119,341$26.00$3,102,866.00View SEC Filing  
11/28/2014Fuad El-HibriMajor ShareholderSell34,577$25.00$864,425.00View SEC Filing  
11/25/2014Fuad El-HibriMajor ShareholderSell9,014$25.00$225,350.00View SEC Filing  
11/25/2014Zsolt HarsanyiDirectorSell8,000$24.82$198,560.00View SEC Filing  
11/12/2014Fuad El-HibriMajor ShareholderSell2,311$25.00$57,775.00View SEC Filing  
11/7/2014Robert KramerCFOSell2,625$24.00$63,000.00View SEC Filing  
4/16/2014Robert KramerCFOSell50,189$24.34$1,221,600.26View SEC Filing  
3/12/2014Adam HaveyEVPSell11,562$27.50$317,955.00View SEC Filing  
3/11/2014Adam HaveyEVPSell17,655$26.96$475,978.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Emergent Biosolutions (NYSE:EBS)
DateHeadline
biz.yahoo.com logoEMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an (NYSE:EBS)
us.rd.yahoo.com - February 24 at 5:37 PM
News IconTechnical Levels in Focus for Emergent BioSolutions Inc (EBS) - Providence Standard (NYSE:EBS)
providencestandard.com - February 24 at 11:45 AM
News IconIs There Upside To Emergent BioSolutions Inc. (NYSE:EBS) Sibanye Gold Limited (NYSE:SBGL)? - Rives Journal (NYSE:EBS)
rivesjournal.com - February 24 at 11:45 AM
News IconEmergent Biosolutions Inc (EBS) Releases Earnings Results, Beats Expectations By $0.13 EPS - Highland Mirror (NYSE:EBS)
www.highlandmirror.com - February 24 at 11:45 AM
finance.yahoo.com logoEdited Transcript of EBS earnings conference call or presentation 23-Feb-17 10:00pm GMT (NYSE:EBS)
finance.yahoo.com - February 24 at 11:45 AM
investornewswire.com logoStrong Sell Recommendations Of Emergent Biosolutions, Inc. (NYSE:EBS) At 0 - Investor Newswire (NYSE:EBS)
www.investornewswire.com - February 23 at 9:53 PM
News IconLooking at the Numbers for Emergent BioSolutions Inc. (NYSE:EBS) - The Standard (NYSE:EBS)
6milestandard.com - February 23 at 9:53 PM
marketexclusive.com logoEMERGENT BIOSOLUTIONS INC. (NYSE:EBS) Files An 8-K Results of Operations and Financial Condition - Market Exclusive (NYSE:EBS)
marketexclusive.com - February 23 at 9:53 PM
sg.finance.yahoo.com logoEmergent Biosolutions posts 4Q profit (NYSE:EBS)
sg.finance.yahoo.com - February 23 at 9:53 PM
News IconStock Buzz on Emergent Biosolutions, Inc. (NYSE:EBS): Can They Meet the Earnings Target of $0.6 - Winfield Review (NYSE:EBS)
winfieldreview.com - February 23 at 4:53 PM
biz.yahoo.com logoQ4 2016 Emergent BioSolutions Inc Earnings Release - After Market Close (NYSE:EBS)
biz.yahoo.com - February 23 at 4:53 PM
finance.yahoo.com logoEmergent BioSolutions Reports Fourth Quarter and Twelve Months 2016 Financial Results; Reaffirms 2017 Guidance and Provides 2020 Goals (NYSE:EBS)
finance.yahoo.com - February 23 at 4:53 PM
biz.yahoo.com logoEmergent BioSolutions Inc Earnings Call scheduled for 5:00 pm ET today (NYSE:EBS)
biz.yahoo.com - February 23 at 4:53 PM
News IconStock Focus: Checking the Chart on Shares of Emergent BioSolutions Inc. (NYSE:EBS) - Searcy News (NYSE:EBS)
searcysentinel.com - February 22 at 10:10 PM
4-traders.com logoEMERGENT BIOSOLUTIONS INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) (NYSE:EBS)
www.4-traders.com - February 22 at 5:09 PM
News IconDrilling Down into the Technicals on Emergent BioSolutions Inc. (NYSE:EBS) - Sherwood Daily (NYSE:EBS)
sherwooddaily.com - February 22 at 6:56 AM
biz.yahoo.com logoEMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex (NYSE:EBS)
biz.yahoo.com - February 22 at 6:56 AM
openpr.com logoEmergent Biosolutions Inc (NYSE:EBS) Investor Investigation over potential Wrongdoing (NYSE:EBS)
www.openpr.com - February 15 at 3:49 AM
News IconEquity Watch: Focus on Technicals for Emergent BioSolutions Inc. (NYSE:EBS) - Midway Monitor (NYSE:EBS)
midwaymonitor.com - February 14 at 10:47 PM
us.rd.yahoo.com logoEmergent BioSolutions Receives BARDA Task Order Valued at Up to $30.5 Million to Develop Viral Hemorrhagic Fever Therapeutics (NYSE:EBS)
us.rd.yahoo.com - February 14 at 3:39 AM
us.rd.yahoo.com logo7:06 am Emergent BioSolutions announces task order from BARDA valued at up to $30.5 mln (NYSE:EBS)
us.rd.yahoo.com - February 14 at 3:39 AM
globenewswire.com logoEmergent BioSolutions Receives BARDA Task Order Valued at Up to $30.5 Million to Develop Viral Hemorrhagic Fever ... - GlobeNewswire (press release) (NYSE:EBS)
globenewswire.com - February 13 at 10:37 PM
News IconTrading Scanner: Following Shares of Emergent BioSolutions Inc. (NYSE:EBS) - The Standard (NYSE:EBS)
6milestandard.com - February 13 at 5:36 PM
finance.yahoo.com logoEmergent BioSolutions Receives BARDA Task Order Valued at Up to $30.5 Million to Develop Viral Hemorrhagic Fever ... - Yahoo Finance (NYSE:EBS)
finance.yahoo.com - February 13 at 8:29 AM
News IconEmergent BioSolutions Reports Third Quarter and Nine Months 2016 Financial Results - Satellite PR News (press release) (NYSE:EBS)
www.satprnews.com - February 10 at 10:21 PM
finance.yahoo.com logoEmergent BioSolutions to Release Fourth Quarter and Full Year 2016 Financial Results and Conduct a Conference Call on February 23, 2017 (NYSE:EBS)
finance.yahoo.com - February 9 at 5:25 PM
News IconEmergent Biosolutions Inc (NYSE:EBS) Investor Investigation over ... - GroundReport (NYSE:EBS)
www.groundreport.com - February 8 at 10:21 PM
us.rd.yahoo.com logoEmergent BioSolutions Initiates NIAID-Funded Phase 1b Clinical Study to Evaluate Broad-Spectrum Antiviral UV-4B for Dengue (NYSE:EBS)
us.rd.yahoo.com - February 1 at 5:24 PM
News IconF-Score in Focus for Emergent BioSolutions Inc. (NYSE:EBS) - The Tribune (NYSE:EBS)
lakecitytribune.com - January 29 at 9:58 PM
News IconTechnical Buzz on Emergent BioSolutions Inc. (NYSE:EBS) - The Tribune (NYSE:EBS)
lakecitytribune.com - January 29 at 3:04 AM
realistinvestor.com logoEmergent Biosolutions, Inc. (NYSE:EBS) Deferred Tax Assets At ... - RealistInvestor.com (NYSE:EBS)
www.realistinvestor.com - January 29 at 3:04 AM
investingnews.com logoEmergent BioSolutions Receives Approval for Large-Scale Manufacturing of BioThrax (NYSE:EBS)
investingnews.com - January 27 at 11:31 PM
us.rd.yahoo.com logoEmergent BioSolutions Receives German Federal Ministry of Health Approval of Building 55 for Large-Scale Manufacturing of BioThrax (NYSE:EBS)
us.rd.yahoo.com - January 27 at 11:31 PM
News IconTrading Lines in Focus for Emergent BioSolutions Inc. (EBS) - Springdale Times (NYSE:EBS)
springdaletimes.com - January 27 at 6:30 PM
News IconStock Update: Estimates & Target in Focus for Emergent Biosolutions, Inc. (NYSE:EBS) - Aiken Advocate (NYSE:EBS)
aikenadvocate.com - January 26 at 6:08 PM
News IconChecking the Levels on Shares of Emergent BioSolutions Inc. (NYSE:EBS) - The Tribune (NYSE:EBS)
lakecitytribune.com - January 24 at 5:31 PM
finance.yahoo.com logoLawsuit for Investors in Shares of Emergent Biosolutions Inc (EBS) Announced by Shareholders Foundation - Yahoo Finance (NYSE:EBS)
finance.yahoo.com - January 23 at 10:14 PM
us.rd.yahoo.com logoLawsuit for Investors in Shares of Emergent Biosolutions Inc (EBS) Announced by Shareholders Foundation (NYSE:EBS)
us.rd.yahoo.com - January 23 at 5:12 PM
News IconInvestor Review: Focusing in on Shares of Emergent BioSolutions Inc. (EBS) - Springdale Times (NYSE:EBS)
springdaletimes.com - January 23 at 12:41 AM
News IconSpot-check on CCI and RSI for Emergent BioSolutions Inc. (EBS) - Rives Journal (NYSE:EBS)
rivesjournal.com - January 21 at 4:49 PM
News IconSell-side Consensus Sees Emergent Biosolutions, Inc. (NYSE:EBS) Going Where Near-Term? - Aiken Advocate (NYSE:EBS)
aikenadvocate.com - January 19 at 11:16 PM
prnewswire.com logoResearch Reports Coverage on Biotech Stocks -- Emergent BioSolutions, Chimerix, VIVUS, and RXi Pharma - PR Newswire (press release) (NYSE:EBS)
www.prnewswire.com - January 19 at 3:17 AM
News IconDownward Trend Continues as Stock Can't Find Its Footing: Emergent BioSolutions Inc. (NYSE:EBS) - Wall Street Beacon (NYSE:EBS)
wsbeacon.com - January 19 at 3:17 AM
News IconEmergent BioSolutions Inc EBS Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NYSE:EBS)
www.bioportfolio.com - January 17 at 8:10 AM
realistinvestor.com logoQuarterly Deferred Tax Assets Of Emergent Biosolutions, Inc. (NYSE:EBS) At $1.483 Millions - RealistInvestor.com (NYSE:EBS)
www.realistinvestor.com - January 14 at 11:20 PM
capitalcube.com logoEmergent BioSolutions, Inc. breached its 50 day moving average in a Bearish Manner : EBS-US : January 12, 2017 (NYSE:EBS)
www.capitalcube.com - January 12 at 5:19 PM
nasdaq.com logoNotable Two Hundred Day Moving Average Cross - EBS (NYSE:EBS)
www.nasdaq.com - January 9 at 5:40 PM
finance.yahoo.com logo7:07 am Emergent BioSolutions offers prelim FY16 results, guides FY17 (NYSE:EBS)
finance.yahoo.com - January 9 at 5:39 PM
biz.yahoo.com logoEMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosur (NYSE:EBS)
biz.yahoo.com - January 9 at 5:39 PM
globenewswire.com logoEmergent BioSolutions Announces Preliminary 2016 Financial Results and Provides 2017 Financial Outlook - GlobeNewswire (press release) (NYSE:EBS)
globenewswire.com - January 9 at 7:46 AM

Social

What is Emergent Biosolutions' stock symbol?

Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Where is Emergent Biosolutions' stock going? Where will Emergent Biosolutions' stock price be in 2017?

5 brokers have issued 1-year price targets for Emergent Biosolutions' shares. Their predictions range from $33.00 to $47.00. On average, they expect Emergent Biosolutions' share price to reach $39.40 in the next twelve months.

When will Emergent Biosolutions announce their earnings?

Emergent Biosolutions is scheduled to release their next quarterly earnings announcement on Wednesday, May, 3rd 2017.

What are analysts saying about Emergent Biosolutions stock?

Here are some recent quotes from research analysts about Emergent Biosolutions stock:

  • According to Zacks Investment Research, "Emergent posted preliminary results for 2016 and its 2017 guidance earlier this month. While preliminary results for 2016 surpassed management’s expectations, which was provided in Dec 2016, its 2017 outlook fell short of market expectations as evident from the drop in its share price following the announcement. However, shares of the company have outperformed the broader industry so far this year. BioThrax is the key product at Emergent’s Biodefense segment and the U.S. government is the primary purchaser of its Biodefense products. The company’s follow-on contract with the CDC for BioThrax, and deals with the BARDA for BioThrax and NuThrax (the next-generation anthrax vaccine candidate) bodes well for growth. Moreover, NuThrax’s approval will be a huge boost for the company. Estimates have gone up ahead of the Q4 results. However, the company’s sole dependence on BioThrax for its top line is concerning." (2/21/2017)

  • Cowen and Company analysts commented, "Emergent BioSolutions pre-announced 2016 financials at the high end of the guidance." (1/9/2017)

  • J P Morgan Chase & Co analysts commented, "This afternoon, Emergent announced 2Q financial results, and while a great deal of focus remains on the upcoming BioThrax and NuThrax contracts, details were limited on these topics and 2016 guidance will not be reinstated until the outcomes are known. While we continue to see high probability of approval for Building 55 (Aug 15 PDUFA date), we believe the Street will need incremental clarity, particularly visibility on pricing in the next BioThrax contract and some color on expectations for the near-term delivery schedule, for the overhang on EBS shares to begin to lift. That said, this clarity is not far off, and we expect an update on both BioThrax and NuThrax by the end of September." (8/5/2016)

Who owns Emergent Biosolutions stock?

Emergent Biosolutions' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (5.00%), Aberdeen Asset Management PLC UK (3.08%), State Street Corp (3.06%), Renaissance Technologies LLC (2.18%), FIL Ltd (1.79%) and Russell Investments Group Ltd. (1.10%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Barry Labinger, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Louis W Sullivan, Marvin L White, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi.

Who sold Emergent Biosolutions stock? Who is selling Emergent Biosolutions stock?

Emergent Biosolutions' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Renaissance Technologies LLC, Guggenheim Capital LLC, Numeric Investors LLC, Allianz Asset Management AG, Federated Investors Inc. PA, GSA Capital Partners LLP and Dimensional Fund Advisors LP. Company insiders that have sold Emergent Biosolutions stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Louis W Sullivan, Marvin L White, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi.

Who bought Emergent Biosolutions stock? Who is buying Emergent Biosolutions stock?

Emergent Biosolutions' stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Aberdeen Asset Management PLC UK, FIL Ltd, FMR LLC, Hodges Capital Management Inc., Congress Asset Management Co. MA, A.R.T. Advisors LLC and Folger Hill Asset Management LP.

How do I buy Emergent Biosolutions stock?

Shares of Emergent Biosolutions can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Emergent Biosolutions stock cost?

One share of Emergent Biosolutions stock can currently be purchased for approximately $29.95.

Emergent Biosolutions (NYSE:EBS) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Earnings History Chart

Earnings by Quarter for Emergent Biosolutions (NYSE:EBS)

Dividend History Chart

Dividend Payments by Quarter for Emergent Biosolutions (NYSE:EBS)

Last Updated on 2/24/2017 by MarketBeat.com Staff